| Similar Articles |
|---|
 |
Information Today
May 26, 2011
Marydee Ojala |
Getting Healthy Information With OvidMD Researchers in the medical field have long relied upon Ovid, part of Wolters Kluwer, databases to provide authoritative information from the medical literature.   |
Information Today
December 15, 2008 |
NursingCenter.com Launches New Features NursingCenter.com from Lippincott Williams & Wilkins, a site for online nursing continuing-education and peer-reviewed content, has been updated with improved navigation and search and new interactive multimedia tools. |
Information Today
April 16, 2001
Barbara Quint |
Wolters Kluwer Adds SilverPlatter Information to Its Collection Dutch mega-publisher Wolters Kluwer has acquired SilverPlatter Information, Inc. The acquisition expands Wolters Kluwer's collection of medical and scientific databases and research tools and extends its reach into more libraries and medical establishments... |
Information Today
May 17, 2004
Barbara Quint |
Ovid Launches Portal Advantage Service with Medical Content Ovid Technologies has announced a Portal Advantage Service to help societies and publishing partners, independent journal publishers, foundations, and corporations to build fully customizable portals. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
Information Today
March 18, 2013 |
Serials Solutions Partners With Wolters Kluwer Health Serials Solutions, a ProQuest business, and Wolters Kluwer Health announced that Lippincott Williams & Wilkins content available on the Ovid institutional research platform will be indexed in the Summon discovery service. |
Information Today
October 11, 2004 |
Weekly News Digest Company Data... Wolters Kluwer Launches New Pharma Services... FAST Launches eCommerce Application... |
The Motley Fool
October 11, 2010
Travis Hoium |
Alexza Shares Plunged: What You Need to Know Alexza Pharmaceuticals shares fell 52% today after the Food and Drug Administration did not clear the company's new drug, AZ-004. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
Information Today
March 31, 2011 |
Wolters Kluwer Health Supports Disaster Relief Efforts in Japan Free online access to emergency, disaster, trauma, and radiation contamination resources to Japanese hospitals and healthcare institutions affected by the disasters will be available via the Wolters Kluwer Health Emergency Resources Portal. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
March 28, 2011
Brian Orelli |
Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news. |
BusinessWeek
May 27, 2010
Michelle Cortez |
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug. |
Information Today
August 2000 |
Harcourt to Be Sole Owner of MD Consult Harcourt, Inc., the global education, training, assessment, and professional information company, has announced it has signed an agreement with publisher Lippincott Williams & Wilkins, to acquire LWW's one-third interest in MD Consult, a clinical-information resource for physicians.... |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
February 1, 2011
Brian Orelli |
Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon. |
Information Today
August 3, 2009 |
Wolters Kluwer Health Launches Interactive Platform for Pharmacology Journal Content AdisOnline has been enhanced to meet the changing market needs of a growing number of clinicians, researchers, and librarians seeking means to greater efficiency. |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Information Today
August 2004
Paula Hane |
New Ovid/LWW CEO Brings a Fresh Look An interview with the president and CEO of Wolters Kluwer Health's global Medical Research division on the company's initiatives and some industry issues. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Give It to Me Straight! Patients want to take a more active role in treatment decisions. Drug facts boxes in DTC ads represent a crucial element of informed consent. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
December 22, 2010
Matt Koppenheffer |
Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume. |
Information Today
December 4, 2006 |
Weekly News Digest Ingenta Releases New Subscription Management Service... Wolters Kluwer Health Launches PubFusion 2.0... ProQuest Adds Oxford University Press Titles to Literature Online... |
Pharmaceutical Executive
May 1, 2011
Jill Wechsler |
Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
